These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 2846576)
41. [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus]. René B; Fossé P; Khélifa T; Jacquemin-Sablon A; Bailly C Bull Cancer; 1997 Oct; 84(10):941-8. PubMed ID: 9435795 [TBL] [Abstract][Full Text] [Related]
42. Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin. Zwelling LA; Michaels S; Erickson LC; Ungerleider RS; Nichols M; Kohn KW Biochemistry; 1981 Nov; 20(23):6553-63. PubMed ID: 6895473 [TBL] [Abstract][Full Text] [Related]
43. Effect of retinoic acid on DNA cleavage and cytotoxicity of topoisomerase II-reactive drugs in a human head and neck squamous carcinoma cell line. Kim HK; Zwelling LA; Sacks PG; Hong WK; Chan D; Silberman L; Glisson BS Cancer Res; 1989 Mar; 49(5):1197-201. PubMed ID: 2537145 [TBL] [Abstract][Full Text] [Related]
45. Effects of the bifunctional antitumor intercalator ditercalinium on DNA in mouse leukemia L1210 cells and DNA topoisomerase II. Markovits J; Pommier Y; Mattern MR; Esnault C; Roques BP; Le Pecq JB; Kohn KW Cancer Res; 1986 Nov; 46(11):5821-6. PubMed ID: 3019538 [TBL] [Abstract][Full Text] [Related]
46. Effect of cell proliferation and chromatin conformation on intercalator-induced, protein-associated DNA cleavage in human brain tumor cells and human fibroblasts. Zwelling LA; Estey E; Silberman L; Doyle S; Hittelman W Cancer Res; 1987 Jan; 47(1):251-7. PubMed ID: 3024817 [TBL] [Abstract][Full Text] [Related]
47. Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Beck WT; Danks MK Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118 [TBL] [Abstract][Full Text] [Related]
48. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells. de Tinguy-Moreaud E; Pourquier P; Montaudon D; Robert J Anticancer Res; 1994; 14(1A):99-103. PubMed ID: 8166463 [TBL] [Abstract][Full Text] [Related]
49. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249 [TBL] [Abstract][Full Text] [Related]
51. Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. Minford J; Pommier Y; Filipski J; Kohn KW; Kerrigan D; Mattern M; Michaels S; Schwartz R; Zwelling LA Biochemistry; 1986 Jan; 25(1):9-16. PubMed ID: 3006754 [TBL] [Abstract][Full Text] [Related]
52. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. de Jong S; Zijlstra JG; de Vries EG; Mulder NH Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222 [TBL] [Abstract][Full Text] [Related]
53. A drug-resistant variant of topoisomerase II alpha in human HL-60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub-nuclear distribution. Boege F; Kjeldsen E; Gieseler F; Alsner J; Biersack H Eur J Biochem; 1993 Dec; 218(2):575-84. PubMed ID: 8269948 [TBL] [Abstract][Full Text] [Related]
54. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA. Lin JH; Castora FJ Arch Biochem Biophys; 1995 Dec; 324(2):293-9. PubMed ID: 8554321 [TBL] [Abstract][Full Text] [Related]
55. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Webb CD; Latham MD; Lock RB; Sullivan DM Cancer Res; 1991 Dec; 51(24):6543-9. PubMed ID: 1660341 [TBL] [Abstract][Full Text] [Related]
56. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines. Eijdems EW; de Haas M; Timmerman AJ; Van der Schans GP; Kamst E; de Nooij J; Astaldi Ricotti GC; Borst P; Baas F Br J Cancer; 1995 Jan; 71(1):40-7. PubMed ID: 7819046 [TBL] [Abstract][Full Text] [Related]
57. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene. Pommier Y; Orr A; Kohn KW; Riou JF Cancer Res; 1992 Jun; 52(11):3125-30. PubMed ID: 1317259 [TBL] [Abstract][Full Text] [Related]
58. Interaction of DNA intercalator 3-nitrobenzothiazolo (3,2-a)quinolinium with DNA topoisomerases: a possible-mechanism for its biological activity. Báez A; Riou JF; Le Pecq JB; Riou G Mol Pharmacol; 1990 Mar; 37(3):377-82. PubMed ID: 2156151 [TBL] [Abstract][Full Text] [Related]
59. Effects of amsacrine and other DNA-intercalating drugs on nuclear and nucleolar structure in cultured V79 Chinese hamster cells and PtK2 rat kangaroo cells. Jensen CG; Wilson WR; Bleumink AR Cancer Res; 1985 Feb; 45(2):717-25. PubMed ID: 3838148 [TBL] [Abstract][Full Text] [Related]
60. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]